►个人简介

工作职位：制药工程教研室副教授，硕士生导师

办公地址：青岛科技大学CCF大楼1101

工作邮箱：shanshandu000@163.com

2011.06硕士毕业于山东大学药学院，2015.01博士毕业于德国海德堡大学。2015.03-2017.03在清华大学生物化工专业从事肝素非抗凝活性相关的博士后研究工作。2017.04-2018.09在药明生物从事抗体类药物相关的细胞培养与工艺开发工作。2018.09来校工作至今，目前主要研究领域包括多糖及抗凝血类药物的开发与研究。

►教学情况

1、本科生课程

药物分析：32课时，本科生，约60人。

►论文

[1] Jia SX, Du S*, et al. Binding ability of methylene blue with heparin dependent on its sulfate level rather than its sulfation location or basic saccharide structure [J] Glycoconj J, 2021, 38(5): 551

[2] Hao yin, Du S*, et al. The hybrid oncolytic peptide NTP-385 potently inhibits adherent cancer cells by targeting the nucleus, Acta Pharmacol Sin (2022). https://doi.org/10.1038/s41401-022-00939-x

[3] Qi YK*, Du S*, et al. Discovery, synthesis, and optimization of teixobactin, a novel antibiotic without detectable bacterial resistance J Pept Sci, 2022, 24, e3428.

[4] Chen XT, Du S*, Qi YK*, et al. DIC/Oxyma based accelerated synthesis  and oxidative folding studies of centipede toxin RhTx, [J] J Pept Sci, 2021, e3368

[5] Yan YS#, Du S#, Yang J, et al. Discovery of enzymatically depolymerized heparins capable of treating Bleomycin-induced pulmonary injury and fibrosis in mice. [J] Carbohydr Polym, 2017 June, 174: 82-88

[6] Du S, Krämer S, Harenberg J, et al. Chromogenic assays for measurement rivaroxaban from EDTA anticoagulated plasma samples [J]. Thromb Haemost. 2015, Jan 113(5): 1149

[7] Du S, Weiss C, Harenberg J, et al. Determination of dabigatran concentrations in patient plasma, serum and urine samples: comparison of six methods [J]. Clin Chem Lab Med, 2015, Jul 53(8):1237

[8] Du S, Harenberg J, Krämer S, et al. Measurement of non-vitamin K antagonist oral anticoagulants in patient plasma using Heptest-STAT coagulation method [J]. Ther Drug Monit. 2015 Jun, 37(3):375

[9] Qi YK, Si Y, Du S, et al. Recent advances in the chemical synthesis and semi-synthesis of poly-ubiquitin-based proteins and probes. [J] Sci China Chem, 2019 Jan, 62: 299-312

[10] Harenberg J, Du S, et al. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study [J]. Clin Chem Lab Med, 2016 Feb, 54(2):275-83

[11] Harenberg J, Du S, et al. Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants [J]. Semin Thromb Hemost. 2015 Mar, 41(2):228-36.

[12] Harenberg J, Du S, Weiss C, et al. Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH [J], J Thromb Haemost, 2014 May, 12: 801-804.

[13] Du S, Harenberg J, Krämer S, Marx S, et al. Determination of dabigatran and rivaroxaban in serum samples from patients on treatment. Poster session presented at: International Society on Thrombosis and Haemostasis 24th Congress, 2013 June 29 - July 4; Amsterdan.

[14] Harenberg J, Kramer S, Du S, et al. Measurement of rivaroxaban and apixaban in serum samples of patients [J]. Eur J Clin Invest. 2014 Aug, 44 (8):743–52.

[15] Harenberg J, Krämer S, Du S, et al. Determination of direct oral anticoagulants from human serum samples [J], Semin Thromb Hemost. 2014 Feb, 40 (1):129 - 34.

[16] Harenberg J, Du S, Krämer S, et al. Novel Methods for Assessing Oral Direct Factor Xa and Thrombin Inhibitors: Use of Point-of-Care Testing and Urine Samples [J], Semin Thromb Hemost 2013 Feb, 39: 66-71.

[17] Harenberg J, Krämer S, Du S, et al. Concept of a point of care test to detect new oral anticoagulants in urine samples [J], Thrombosis Journal 2013 Aug, 11: 15.

[14] Yan YS, Guan CG, Du S, et al. Effects of enzymatically depolymerized low molecular weight heparins on CCl4-induced liver fibrosis. [J] Front in pharmacol, 2017 Aug, 8:514

[18] Li Y, Luo JY, Cui HF, Zheng L, Du S, et al. Study on anti-metasis of heparin derivatives as ligand antagonist of p-selectin [J]. Biomed Pharmacother 2010 Dec, 64: 654-658.

[19]杜姗姗,崔慧斐.低分子肝素分子量测定方法[J],药物分析杂志, 2011, 31(2): 402-408.

[20]杜姗姗,桑青,崔慧斐.低分子肝素分子量测定用对照品的研制[J],药物分析杂志, 2012, 32 (11): 1976–1980.

►承担的科研项目

[1] 202101-202312，国自然青年科学基金项目，82003647，肝素非抗凝活性治疗特发性肺纤维化及作用机制研究，在研，项目负责人。

[2] 201907-202206，山东省基金，ZR2019BH045，肝素及其衍生物对脓毒症治疗作用的研究，在研，项目负责人。

[3] 2016.01–2017.12，中国博士后基金，2015M581121，肝素的修饰及其对治疗特发性肺纤维化影响规律的研究，已结题，项目负责人。